AlphAIalphai — Financial news for AI agents
MarketBeatAPR 182 min read$ABSI

Absci (NASDAQ:ABSI) Stock Price Up 11% - Still a Buy?

Absci (NASDAQ:ABSI) shares rose 11% on Friday, despite missing quarterly earnings and revenue expectations significantly. The company operates with a negative net margin and analysts forecast a negative EPS for the fiscal year, leading to a consensus "Hold" rating with an average price target of $6.44. Insider ownership is 10.49% (including a recent purchase by Andreas Busch) and institutional ownership is approximately 52%.

Original reporting
MarketBeat · MarketBeat
Published Apr 18, 2026, 1:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 18, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Absci (NASDAQ:ABSI) Stock Price Up 11% - Still a Buy? — source image
Source · MarketBeat
Decision brief

The 30-second read

$ABSINeutralLow
01

Why it matters

The price increase despite poor earnings indicates market speculation or anticipation of future positive developments.

02

Market read

The news has limited broader market impact but is relevant for biotech sector traders and investors.

03

What to watch

Potential for news-driven short-term trading; insider buying suggests some confidence in future prospects despite current losses.

Timing: short-term

Background

Absci operates in the biotech sector, often subject to volatility based on clinical trial results and earnings reports.

Company-level read

Ticker impact

$ABSINeutralMedium confidence
Context

The news concerns Absci's stock performance and financial outlook.

Expected impact

Moderate short-term increase followed by potential correction; long-term outlook remains uncertain due to negative earnings trajectory.

Evidence & confidence

The significant price jump despite poor financial results suggests speculative behavior; technical indicators are not provided, limiting precise prediction.

Market effects

Sector

Potential positive sentiment in biotech and life sciences sectors due to stock rebound.

Regional

Limited regional impact; primarily relevant to U.S. markets.

Global

Minimal; company-specific news with limited global implications.

Counterpoint

What could challenge this read

The stock's rise may be a short-term overshoot; fundamentals remain weak, and a correction could ensue.

Key entities

  • Company
    Absci

    Biotech firm specializing in drug discovery and development.

  • Insider
    Andreas Busch

    Recent insider purchase indicating some confidence in the company's future.

Read at source← All news

Related articles

AUG 19
$ABSIMed

Absci (ABSI) Q2 2026 Earnings Call Transcript

Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.

fool.com3 min
AUG 11
$ABSIHighAI 9/10

Why is Absci stock tumbling today?

Absci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.

investing.com3 min
AUG 11
$ABSIMed

Absci Corp (ABSI): Results of Operations and Financial Condition

Absci Corp (ABSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly

SEC EDGAR 8-K6 min
JUN 26
$ABSIMed

Absci (NASDAQ:ABSI) Shares Gap Up Following Analyst Upgrade

Absci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.

themarketsdaily.com3 min
AUG 28
$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

fool.com2 min